Behavioral Rehabilitation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 116 Pages
多くの国がすでにCOVID-19のワクチンを承認しています。たとえば、2020年12月、世界保健機関（WHO）は、Pfizer/BioNTechのCOVID-19mRNAワクチンの緊急使用のためのバリデーションを世界的に発表しました。2021年1月にNature Reviews Neurologyに掲載されたKatya Numbers et al.の調査研究によると、認知症などの精神障害を持つ人々は、認知症状によって保護手順や生活環境の遵守を困難にするため、COVID-19感染のリスクが高いと述べています。介護施設では、ウイルスの拡散を促進します。さらに、認知症の高齢者は、認知症のない人よりも深刻な病気の結果をもたらす可能性が高くなります。Lewy Body Societyによると、認知症および関連障害のある人は、手を洗う、推奨される物理的距離を維持する、COVID-19の症状を監視する、家にいるなど、ウイルスの拡散を防ぐためにつくられた政府のガイドラインに従うのが難しいと述べています。より重度の認知症の人は、短期記憶喪失と認知障害のためにガイドラインを理解または覚えることができない場合があります。英国国家統計局2020によると、認知症とアルツハイマー病は、英国でCOVID-19に関連した死亡者の中で最も一般的な既往症であると報告されています。
The Behavioral Rehabilitation Market is estimated to grow with a steady CAGR of 3.5 % during the forecast period from 2021-2026.
The COVID-19 pandemic is expected to have a slightly negative impact on the market. At present, countries across the globe are facing a considerable threat of COVID-19 (coronavirus). Many pharmaceutical and biotechnological companies are focusing their R&D activities on manufacturing antiseptic products and vaccines to meet the increased demand from customers. Owing to the situation, most pharmaceutical and biotechnological companies have been focusing their R&D departments on identifying new molecules or leads for the treatment of this disease. Many countries have already approved a vaccine for COVID-19. For instance, in December 2020, the World Health Organization (WHO) issued the emergency use validation of Pfizer/BioNTech COVID-19 mRNA vaccine globally. According to a research study by Katya Numbers et al., published in Nature Reviews Neurology in January 2021, stated that people with mental disorders like dementia are at high risk of COVID-19 infection because cognitive symptoms cause difficulty with following safeguarding procedures and living arrangements in care homes facilitate viral spread. Furthermore, older population with dementia are also more likely to have more severe disease consequences than those without dementia. As per Lewy Body Society, stated that people with dementia and related disorders find harder to follow government guidelines designed to prevent the spread of the virus such as washing hands, maintaining the recommended physical distance, monitoring COVID-19 symptoms and staying at home. People with more severe dementia may not be able to understand or remember the guidelines due to their short-term memory loss and cognitive impairment. As per Office for National Statistics UK 2020, stated that dementia and Alzheimer's disease were the most common pre-existing conditions found among deaths involving COVID-19 in United Kingdom.
Furthermore, due to the COVID-19 pandemic, lots of families are facing a significant economic burden, which can lead to an even greater inclination toward letting go of treatment options. Moreover, the pandemic can also have a negative impact on the new product launches, which are estimated to be the most prominent factor of the growth of the market. For instance, in April 2020, Biogen announced that it had delayed Alzheimer's and dementia drug filing to FDA while citing the complexity of data analysis and impact on COVID-19 on its R&D resources
According to the statistics provided by the Mental Health Foundation in 2018, mental health problems were one of the primary causes of rising medical concerns. Furthermore, mental and behavioral health problems are considered to be the primary cause of disability in the age group of 20-29 years, since the past few decades. According to the same source, every year, a large number of people were diagnosed with mental illnesses in the United States. According to the United States Department of Health and Human Services (DHHS) in 2018, one in every five (20%) children and adolescents suffer from mental health disorder at some point in their life. At least, 1 in 10, or about 6 million people suffered serious emotional disturbance at some point in their life.
The treatments for behavioural disorders mainly focuses on behavioural treatment and medication. Parent management training and family therapy are considered quite effective for managing behavioural disorders. Additionally, cognitive behavioral therapy treatment is the most commonly used mechanism for managing the symptoms of behavioral disorders. However, medication treatment for these disorders is targeted toward treating underlying or co-occurring disorders, such as attention deficit hyperactivity disorder (ADHD), depression or anxiety. These developments re expected to positively affect market development.
Anxiety Disorder is Expected to Significant Share of the Global Behavioral Rehabilitation Market Over the Forecast Period
The anxiety disorders are different from normal feelings of anxiousness and involve excessive anxiety or fear. According to Our World in Data (OWID), an estimated 284 million people experienced an anxiety disorder in 2017, globally, making it the most prevalent mental health or neurodevelopmental disorder. Whereas, the Anxiety and Depression Association of America (ADAA) states that anxiety disorders are the most common mental illness in the United States, affecting 40 million adults of age 18 and older, i.e., 18.1% of the population each year. Even though anxiety disorders are very much treatable, only 36.9% of those suffering receive treatment, according to the Anxiety and Depression Association of America. Individuals with an anxiety disorder are three to five times more likely to visit the doctor and six times more likely to be hospitalized for psychiatric conditions than those who do not have anxiety disorders. The roots of anxiety disorders are presently unknown but probably involve a combination of factors, including genetic, psychological, environmental, and developmental.
However, many antidepressants, including escitalopram (Lexapro) and fluoxetine (Prozac), can alleviate anxiety disorders and help people lead a normal and productive life. Furthermore, increase in research and development on treatment of anxiety disorders due to overall increasing prevalence of this disorder is expected to drive the market growth over the forecast period.
North America is Expected to Hold the Major Share of the Market Over the Forecast Period
North America is the largest behavioral rehabilitation market in the world, with the United States occupying the major share. The developed countries, including the United States and Canada, have been witnessing a large number of mental health rehabilitation centers opening for the past decade. According to the NIH, in the United States, the prevalence of personality disorder was 9.1%. As per the National Institute of Mental Health, 2018, in the United States, 21.4% of American adults have experienced mood disorders at some point in their lives. It has also been found that there are various new launches in the behavioral health market in North America. For instance, in September 2019, Hackensack Meridian Health launched the first medically integrated urgent care center with behavioral health in the country, with an aim to improve access, better coordinate care, and innovate treatment for people struggling with mental health issues and addiction. Therefore, in addition, favorable government initiatives and a large number of reimbursement options are two of the other factors fueling growth in this region. The Affordable Care Act categorizes behavioral disorders as essential healthcare, which helps in covering the major part of the treatments. Therefore, all these factors affect the growth of the market.
The market is slightly consolidated with a few major players. Currently, many companies are focusing on the development and introduction of novel products and services into the market which is easily affordable and accessible and entering into strategic collaborations and partnerships to enhance their market positions. Some of the key innovations in the market are: In February 2019, Acadia Healthcare acquired the operations and real estate associated with Whittier Pavilion, a premier behavioral healthcare facility located in Haverhill, Massachusetts, and Mission Treatment operates nine comprehensive treatment centers in California, Nevada, Arizona, and Oklahoma.